|
|
|
|
|
|
|
13.11.25 - 13:27
|
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights (Business Wire)
|
|
|
- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors -
- On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder (“GAD”) in Q1 20261 -
- Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) -
-The Company's cash position as at September 30, 2025 after giving effect to the net proceeds of the Registered Direct Offering is US$248 million -
- Repayment of outstanding convertible debentures to High Trail Special Situations LLC and debt retired in full -
- Company to host conference call and webcast at 8:00 a.m. ET today -TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developin...
|
|
|
|
|
|
|
06.11.25 - 13:36
|
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025 (Business Wire)
|
|
|
- Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 -
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (”Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025.
CONFERENCE CALL DETAILS:
Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International)
Conference ID: CYBN1113
Webcast: Register for the webcast here
The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page.
About Cybin
Cybin is a breakthrough Phase 3 clinical-stage neuropsychiatry company committed to revolutionizing mental healthc...
|
|
|
31.10.25 - 21:24
|
Cybin Announces Closing of $175 Million Registered Direct Offering (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Cybin Inc. (Cboe CA: CYBN) (NYSE American: CYBN) (“Cybin” or the “Company”), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, is pleased to announce that it has closed its previously announced registered direct offering of 22,277,750 common shares in the capital of the Company (a “Common Share”) and, in lieu of Common Shares to certain investors, 4,605,500 pre-funded Common Share purchase warrants (the “Pre-Funded Warrant”) at a price of US$6.51 per Common Share or Pre-Funded Warrant for aggregate gross proceeds of US$175,009,911.45 (the “Offering”).
The financing includes new and existing investors, including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Manag...
|
|
|
|
|
|
|
|
|
21.10.25 - 14:01
|
BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor (The Newswire)
|
|
|
VANCOUVER, British Columbia, October 21, 2025 – TheNewswire - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, has announced that it has appointed Doug Drysdale, former CEO of Cybin Inc. (“Cybin”) (NYSE: CYBN) as Corporate Advisor to advance BetterLife's product BETR-001's non psychiatric indications with focus on cluster headache and migraine.
At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.
Earlier in his career, as Founding CEO of Alvogen, Mr. Drysdale grew the company from inception to $500 million in revenues across 35 countries in 5.5 years, establishing research and development (“R&D”) in New Jersey, a CRO in India, and a 50-product U....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.09.25 - 13:33
|
Cybin Announces Senior Leadership Changes (Business Wire)
|
|
|
Doug Drysdale to step down as Chief Executive Officer; Eric So appointed Interim Chief Executive Officer
This news release constitutes a “designated news release” for the purposes of Cybin's prospectus supplement dated February 10, 2025, to its short form base shelf prospectus dated August 17, 2023, as amended December 22, 2023, April 8, 2024, and January 6, 2025.TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe Canada:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, announced that, effective September 2, 2025, Doug Drysdale will step down as the Company's Chief Executive Officer. The Company's Co-Founder and President, Eric So, has been appointed as Interim Chief Executive Officer by the Board of Directors.
“Cybin was founded with a singular mission: to transform the treatment paradigm for mental health. With a solid f...
|
|
|
18.08.25 - 23:36
|
Cybin Announces Results of Annual Meeting of Shareholders (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the “Meeting”). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:
1. Appointment of Auditor
Zeifmans LLP was appointed auditor of Cybin until the next annual meeting of shareholders at renumeration to be fixed by the directors of Cybin. Voting results are set out below:
Votes For
Votes Withheld
#
%
#
%
11,206,201
99.485
58,010
0.515%
2. ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
